These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 30123981)

  • 1. Predictive value of venous thromboembolism (VTE)-BLEED to predict major bleeding and other adverse events in a practice-based cohort of patients with VTE: results of the XALIA study.
    Klok FA; Barco S; Turpie AGG; Haas S; Kreutz R; Mantovani LG; Gebel M; Herpers M; Bugge JP; Kostantinides SV; Ageno W
    Br J Haematol; 2018 Nov; 183(3):457-465. PubMed ID: 30123981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism.
    Robertson L; Yeoh SE; Ramli A
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011088. PubMed ID: 29244199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Type of Oral Anticoagulant Dispensed With Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for Venous Thromboembolism.
    Pawar A; Gagne JJ; Gopalakrishnan C; Iyer G; Tesfaye H; Brill G; Chin K; Bykov K
    JAMA; 2022 Mar; 327(11):1051-1060. PubMed ID: 35289881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism.
    Klok FA; Barco S; Konstantinides SV
    Thromb Haemost; 2017 Jun; 117(6):1164-1170. PubMed ID: 28276566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Four Bleeding Risk Scores to Identify Rivaroxaban-treated Patients With Venous Thromboembolism at Low Risk for Major Bleeding.
    Kline JA; Jimenez D; Courtney DM; Ianus J; Cao L; Lensing AW; Prins MH; Wells PS
    Acad Emerg Med; 2016 Feb; 23(2):144-50. PubMed ID: 26765080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study.
    Ageno W; Mantovani LG; Haas S; Kreutz R; Monje D; Schneider J; van Eickels M; Gebel M; Zell E; Turpie AG
    Lancet Haematol; 2016 Jan; 3(1):e12-21. PubMed ID: 26765643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative risk of major bleeding with rivaroxaban and warfarin: Population-based cohort study of unprovoked venous thromboembolism.
    Kohn CG; Bunz TJ; Beyer-Westendorf J; Coleman CI
    Eur J Haematol; 2019 Feb; 102(2):143-149. PubMed ID: 30328143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study.
    Larsen TB; Skjøth F; Kjældgaard JN; Lip GYH; Nielsen PB; Søgaard M
    Lancet Haematol; 2017 May; 4(5):e237-e244. PubMed ID: 28411120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of major bleeding in patients receiving DOACs for venous thromboembolism: A prospective cohort study.
    Vedovati MC; Mancuso A; Pierpaoli L; Paliani U; Conti S; Ascani A; Galeotti G; Di Filippo F; Caponi C; Agnelli G; Becattini C
    Int J Cardiol; 2020 Feb; 301():167-172. PubMed ID: 31761402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the predictive value of the bleeding prediction score VTE-BLEED for recurrent venous thromboembolism.
    Klok FA; Presles E; Tromeur C; Barco S; Konstantinides SV; Sanchez O; Pernod G; Raj L; Robin P; Le Roux PY; Hoffman C; Mélac S; Bertoletti L; Girard P; Laporte S; Mismetti P; Meyer G; Leroyer C; Couturaud F;
    Res Pract Thromb Haemost; 2019 Jul; 3(3):364-371. PubMed ID: 31294323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. XALIA-LEA: An observational study of venous thromboembolism treatment with rivaroxaban and standard anticoagulation in the Asia-Pacific, Eastern Europe, the Middle East, Africa and Latin America.
    Kreutz R; Mantovani LG; Haas S; Monje D; Schneider J; Bugge JP; Gebel M; Tamm M; Ageno W; Turpie AGG
    Thromb Res; 2019 Apr; 176():125-132. PubMed ID: 30825694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and safety of rivaroxaban versus warfarin in patients with provoked venous thromboembolism.
    Coleman CI; Turpie AGG; Bunz TJ; Beyer-Westendorf J
    J Thromb Thrombolysis; 2018 Oct; 46(3):339-345. PubMed ID: 29881958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of rivaroxaban versus warfarin in patients with unprovoked venous thromboembolism: A propensity-score weighted administrative claims cohort study.
    Coleman CI; Peacock WF; Bunz TJ; Beyer-Westendorf J
    Thromb Res; 2018 Aug; 168():31-36. PubMed ID: 29883907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk assessment tools for bleeding in patients with unprovoked venous thromboembolism: an analysis of the PLATO-VTE study.
    Guman NAM; Becking AL; Weijers SS; Kraaijpoel N; Mulder FI; Carrier M; Jara-Palomares L; Di Nisio M; Ageno W; Beyer-Westendorf J; Klok FA; Vanassche T; Otten JMMB; Cosmi B; Peters MJL; Wolde MT; Delluc A; Sanchez-Lopez V; Porreca E; Bossuyt PMM; Gerdes VEA; Büller HR; van Es N; Kamphuisen PW
    J Thromb Haemost; 2024 Sep; 22(9):2470-2481. PubMed ID: 38866248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term rivaroxaban for the treatment of acute venous thromboembolism in patients with active cancer in a prospective multicenter trial.
    Yhim HY; Choi WI; Kim SH; Nam SH; Kim KH; Mun YC; Oh D; Hwang HG; Lee KW; Song EK; Kwon YS; Bang SM
    Korean J Intern Med; 2019 Sep; 34(5):1125-1135. PubMed ID: 29788694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rivaroxaban for the treatment of venous thromboembolism. The SWIss Venous ThromboEmbolism Registry (SWIVTER).
    Kucher N; Aujesky D; Beer JH; Mazzolai L; Baldi T; Banyai M; Hayoz D; Kaeslin T; Korte W; Escher R; Husmann M; Frauchiger B; Baumgartner I; Spirk D
    Thromb Haemost; 2016 Aug; 116(3):472-9. PubMed ID: 27346301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and safety of rivaroxaban versus warfarin in obese patients with acute venous thromboembolism: analysis of electronic health record data.
    Costa OS; Beyer-Westendorf J; Ashton V; Milentijevic D; Moore KT; Bunz TJ; Coleman CI
    J Thromb Thrombolysis; 2021 Feb; 51(2):349-358. PubMed ID: 32588288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
    Coleman CI; Bunz TJ; Turpie AGG
    Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Analysis of the Risk Factors Associated with Minor Bleeding in Patients with Venous Thromboembolism during Treatment with Direct Oral Anticoagulants].
    Sunaga T; Shimizu T; Nakamura S; Takahashi N; Higashino M; Matsui M; Hozumi T; Ebato M; Suzuki H; Kogo M; Watanabe T; Sasaki T
    Yakugaku Zasshi; 2019; 139(3):461-467. PubMed ID: 30828024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticoagulant treatment for venous thromboembolism: A pooled analysis and additional results of the XALIA and XALIA-LEA noninterventional studies.
    Haas S; Mantovani LG; Kreutz R; Monje D; Schneider J; Zell ER; Tamm M; Gebel M; Bugge JP; Ageno W; Turpie AGG
    Res Pract Thromb Haemost; 2021 Mar; 5(3):426-438. PubMed ID: 33870028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.